0001104659-21-008179.txt : 20210127 0001104659-21-008179.hdr.sgml : 20210127 20210127161718 ACCESSION NUMBER: 0001104659-21-008179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210125 FILED AS OF DATE: 20210127 DATE AS OF CHANGE: 20210127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pellizzari Christine A CENTRAL INDEX KEY: 0001127430 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 21559940 MAIL ADDRESS: STREET 1: 10 FINDERNE AVENUE CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER NAME: FORMER CONFORMED NAME: PELLIZZARI CHRISTINE A DATE OF NAME CHANGE: 20001030 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 4 1 tm213966-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-01-25 0 0001104506 INSMED Inc INSM 0001127430 Pellizzari Christine A 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 0 1 0 0 Chief Legal Officer Common Stock 2021-01-25 4 M 0 15000 10.85 A 155721 D Common Stock 2021-01-25 4 S 0 15000 42.95 D 140721 D Common Stock 2021-01-25 4 M 0 6000 10.85 A 146721 D Common Stock 2021-01-25 4 S 0 6000 43.84 D 140721 D Common Stock 2021-01-26 4 M 0 2600 10.85 A 143321 D Common Stock 2021-01-26 4 S 0 2600 44.04 D 140721 D Stock Option (right to buy) 10.85 2021-01-25 4 M 0 15000 0 D 2026-05-19 Common Stock 15000 30150 D Stock Option (right to buy) 10.85 2021-01-25 4 M 0 6000 0 D 2026-05-19 Common Stock 6000 24150 D Stock Option (right to buy) 10.85 2021-01-26 4 M 0 2600 0 D 2026-05-19 Common Stock 2600 21550 D The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 15,000 shares sold at prices ranging from $42.75 to $43.58 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 6,000 shares sold at prices ranging from $43.75 to $43.94 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 2,600 shares sold at prices ranging from $43.75 to $44.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant. /s/ Christine Pellizzari 2021-01-27